Clinical Trial Update: Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating O&D-001 Injection for relapsed or refractory multiple myeloma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• O&D-001 Injection

Snippet

Sponsor: O&D BioTech Group CO., Limited | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING